Götte M
Research Laboratory, Department of Gynecology and Obstetrics, Münster University Hospital, Münster, Germany.
Minerva Ginecol. 2010 Dec;62(6):559-71.
Micro RNAs (miRNAs) are small non-coding RNAs which regulate fundamental cellular and developmental processes at the transcriptional and translational level. In breast cancer, expression of miRNAs is frequently dysregulated. Both tumor suppressor activity and oncogenic properties have been assigned to specific miRNAs, which modulate virtually all relevant stages of breast cancer progression, including tumor cell proliferation, apoptosis resistance, cancer cell migration, invasiveness and metastasis, tumor angiogenesis and cancer stem cell self-renewal. miRNA expression has been studied by microarray profiling, bead-based technologies and quantitative real-time PCR in archived formalin-fixed paraffin-embedded tumor specimens as well as blood and serum samples, allowing to identify specific miRNAs as novel diagnostic, prognostic and predictive markers. Moreover, the investigation of single nucleotide polymorphisms both in putative miRNA binding sites in the 3'UTRs of target genes, as well as in miRNA-endocing genes have revealed their diagnostic potential. In vitro experiments employing established breast cancer cell lines and in vivo xenograft studies have demonstrated the efficacy of oligonucleotide-based overexpression and inhibitor approaches of miRNA-targeted experimental therapies. Numerous studies have identified specific targets of miRNA action in breast cancer, including the established markers Her2/neu and ERalpha, TP53, and markers of angiogenesis. The future application of locked-nucleic acid miRNA inhibitors, and synergistic approaches involving conventional breast cancer therapeutics opens up promising new perspectives in breast cancer therapy.
微小RNA(miRNA)是一类小的非编码RNA,它们在转录和翻译水平上调节基本的细胞和发育过程。在乳腺癌中,miRNA的表达常常失调。特定的miRNA既具有肿瘤抑制活性,又具有致癌特性,它们几乎调节乳腺癌进展的所有相关阶段,包括肿瘤细胞增殖、抗凋亡、癌细胞迁移、侵袭和转移、肿瘤血管生成以及癌症干细胞自我更新。已通过微阵列分析、基于微珠的技术以及定量实时PCR,在存档的福尔马林固定石蜡包埋肿瘤标本以及血液和血清样本中研究了miRNA的表达,从而能够鉴定出特定的miRNA作为新的诊断、预后和预测标志物。此外,对靶基因3'非翻译区(3'UTR)中假定的miRNA结合位点以及miRNA编码基因中的单核苷酸多态性进行研究,揭示了它们的诊断潜力。利用已建立的乳腺癌细胞系进行的体外实验以及体内异种移植研究,证明了基于寡核苷酸的miRNA过表达和抑制剂方法在miRNA靶向实验性治疗中的有效性。大量研究已经确定了miRNA在乳腺癌中的特定作用靶点,包括已确定的标志物Her2/neu和雌激素受体α(ERα)、TP53以及血管生成标志物。锁核酸miRNA抑制剂的未来应用以及涉及传统乳腺癌治疗药物的协同方法,为乳腺癌治疗开辟了有前景的新方向。